Allarity Therapeutics, Inc.

AI-generated fair value estimate for this company.

Method: Risk-adjusted probability-weighted NPV (rNPV): $80M assumed exit/licensing value for lead asset stenoparib (PARP inhibitor, Phase 2 in ovarian cancer/SCLC with companion diagnostic); 12% probability of reaching that outcome; 3-year time horizon; 20% biotech-specific discount rate; plus current net debt of -$1.69M ($19.81M cash less $21.5M debt); 15.91M shares outstanding.

Reasoning: Allarity is a clinical-stage oncology biotech with minimal revenue and no near-term cash flows, so a standard DCF is not meaningful; a probability-weighted rNPV of a realistic licensing/M&A outcome for its lead precision-medicine candidate, net of its current debt position, is the most defensible approach for a pre-commercial biotech.